News Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:11 19/09/2024 BST			5-day change	1st Jan Change
3.020 ^HKD	+2.03%		+3.07%	-19.03%

08-30	Citi Upgrades Luye Pharma to Buy From Sell; Price Target is HK$4	MT
08-28	Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

100% Free Registration

Citi Upgrades Luye Pharma to Buy From Sell; Price Target is HK$4	08-30	MT
Luye Pharma : Announces 2024 Half Year Results	08-29	PU
Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-28	CI
Luye Pharma : mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China	08-13	PU
Luye Pharma Group's Subsidiary's Investor Buys 25% Stake in Nanjing Luye for 1 Billion Yuan	08-13	MT
China Approves Luye Pharma's Anti-Psychotic Drug for Trials; Shares Jump 5%	08-06	MT
Luye Pharma : Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China	08-06	PU
Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trials for Innovative Dual TAAR1/5-HT2CR Agonist	08-05	CI
Luye Pharma Group Gets US FDA Marketing Approval for Schizophrenia Injectable	07-29	MT
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder	07-28	CI
Luye Pharma : Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating ...	07-28	PU
Luye Pharma : Will Receive RMB 1.6 Billion Strategic Investment for Shenzhen Luye	07-23	PU
Luye Pharma Group to Divest 34.8% Stake in Shenzhen Unit	07-23	MT
Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. for CNY 1.0 billion.	07-22	CI
Chinese Regulator Approves Luye Pharma Group's New Drug for Marketing	07-04	MT
Luye Pharma : Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for ...	07-04	PU
Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China	07-04	CI
Luye Pharma : Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI ...	06-28	PU
Luye Pharma Group Ltd. Announces Manufacturing Facility of Paliperidone Palmitate Extended-Release Injectable Suspension Passed Pai by U.S. FDA with No FDA-483	06-27	CI
Luye Pharma Secures Chinese Medical Regulatory Approval for Parkinson’s Disease Treatment	06-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Pharmaceuticals

Filters